| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $9.1M | +35.4% | +1524.0% |
| SG&A Expense | $5.9M | -4.3% | -44.9% |
| Operating Income | -$15.0M | +35.9% | +36.4% |
| Net Income | -$13.6M | +36.5% | +41.0% |
| EPS (Basic) | -$2.01 | +38.0% | +43.2% |
| EPS (Diluted) | -$2.01 | +38.0% | +43.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.8M | -24.5% | -12.9% |
| Current Assets | $196.3M | -5.4% | +48.0% |
| Total Assets | $211.8M | -8.3% | -22.3% |
| Current Liabilities | $5.7M | -58.9% | -44.6% |
| Total Liabilities | $91.3M | -8.0% | -5.1% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$29.5M | — | — |
| Investing Cash Flow | $17.7M | — | — |
| Financing Cash Flow | $7.3M | — | — |
| $120.4M |
| -8.5% |
| -31.7% |